We are live on
!
Find out more
DMKJ
David M. Knott Jr Portfolio holdings
AUM
$168M
1-Year Est. Return
60.36%
This Fund
S&P 500
This Quarter
Est. Return
-12.56%
1 Year Est. Return
+60.36%
3 Year Est. Return
+143.93%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$212M
AUM Growth
-$64.6M
(-23%)
Cap. Flow
-$15M
Cap. Flow
% of AUM
-7.08%
Top 10 Holdings %
Top 10 Hldgs %
72.97%
Holding
103
New
14
Increased
10
Reduced
14
Closed
19
Top Buys
| 1 |
Ultragenyx Pharmaceutical
RARE
|
+$2M |
| 2 |
Myriad Genetics
MYGN
|
+$1.92M |
| 3 |
Cogent Biosciences
COGT
|
+$1.67M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$1.38M |
| 5 |
TECX
Tectonic Therapeutic
TECX
|
+$1.3M |
Top Sells
| 1 |
Calumet Specialty Products
CLMT
|
+$5.56M |
| 2 |
VRNA
Verona Pharma
VRNA
|
+$4.26M |
| 3 |
Invesco AAA CLO Floating Rate Note ETF
ICLO
|
+$3.36M |
| 4 |
Janus Henderson AAA CLO ETF
JAAA
|
+$1.96M |
| 5 |
Viking Therapeutics
VKTX
|
+$1.57M |
Sector Composition
| 1 | Healthcare | 33.25% |
| 2 | Materials | 20.41% |
| 3 | Financials | 19.12% |
| 4 | Communication Services | 8.29% |
| 5 | Industrials | 1.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Calumet Specialty Products
CLMT
$3.58B
| $41.8M | 19.73% |
3,297,194
-354,167
| -10% | -$5.56M |
|
2
Apollo Global Management
APO
$71.1B
| $30.8M | 14.54% |
225,000
| – | – |
|
|
3
Janus Henderson AAA CLO ETF
JAAA
$29B
| $28M | 13.2% |
551,763
-38,634
| -7% | -$1.96M |
|
4
Alphabet (Google) Class C
GOOG
$4.32T
| $17.5M | 8.27% |
112,220
| – | – |
|
5
DocGo
DCGO
$63M
| $8.11M | 3.82% |
3,070,850
| – | – |
|
6
Pfizer
PFE
$143B
| $6.45M | 3.04% |
254,537
| – | – |
|
7
Xeris Biopharma Holdings
XERS
$1.5B
| $6.09M | 2.88% |
1,110,000
+110,000
| +11% | +$444K |
|
|
VRNA
8
DELISTED
Verona Pharma
VRNA
| $5.59M | 2.64% |
88,000
-71,300
| -45% | -$4.26M |
|
9
JPMorgan Chase
JPM
$912B
| $5.15M | 2.43% |
20,985
| – | – |
|
10
Catalyst Pharmaceutical
CPRX
| $5.14M | 2.43% |
212,000
+2,000
| +1% | +$45K |
|
11
Travere Therapeutics
TVTX
$5.14B
| $4.09M | 1.93% |
228,000
| – | – |
|
12
Protagonist Therapeutics
PTGX
$8.49B
| $3.68M | 1.73% |
76,000
+23,632
| +45% | +$990K |
|
13
BioCryst Pharmaceuticals
BCRX
$2.32B
| $3.45M | 1.63% |
460,000
+20,000
| +5% | +$161K |
|
|
AVDL
14
DELISTED
Avadel Pharmaceuticals
AVDL
| $3.34M | 1.57% |
426,000
+79,096
| +23% | +$662K |
|
|
ESGR
15
DELISTED
Enstar Group
ESGR
| $2.49M | 1.18% |
7,500
| – | – |
|
16
Ardelyx
ARDX
$1.27B
| $2.42M | 1.14% |
493,807
-118,463
| -19% | -$636K |
|
17
OmniAb
OABI
$296M
| $2.36M | 1.11% |
982,336
-112,169
| -10% | -$367K |
|
18
CSX Corp
CSX
$94.6B
| $2.06M | 0.97% |
70,000
| – | – |
|
19
AllianceBernstein
AB
$3.58B
| $1.84M | 0.87% |
48,000
| – | – |
|
|
20
Invesco AAA CLO Floating Rate Note ETF
ICLO
$509M
| $1.8M | 0.85% |
70,502
-130,985
| -65% | -$3.36M |
|
|
21
Ultragenyx Pharmaceutical
RARE
$2.98B
| $1.74M | 0.82% |
+48,000
| New | +$2M |
|
22
Syndax Pharmaceuticals
SNDX
$2.01B
| $1.57M | 0.74% |
128,000
| – | – |
|
|
23
Myriad Genetics
MYGN
$585M
| $1.42M | 0.67% |
+160,000
| New | +$1.92M |
|
|
24
Cogent Biosciences
COGT
$6.48B
| $1.28M | 0.6% |
+213,302
| New | +$1.67M |
|
25
Panagram BBB-B CLO ETF
CLOZ
$762M
| $1.27M | 0.6% |
47,807
| – | – |
|
Similar funds
DI
WFS
CCG
7CM
TT
MAG
PFA
CW